| Mr Richard E Priday, CRNA | |
|
5301 South Congress Ave, Atlantis, FL 33462 | |
| (561) 965-7300 | |
| (561) 967-2101 |
| Full Name | Mr Richard E Priday |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 16 Years |
| Location | 5301 South Congress Ave, Atlantis, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386817195 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163W00000X | Registered Nurse | RN 3405532 (Florida) | Secondary |
| 367500000X | Nurse Anesthetist, Certified Registered | ARNP3405532 (Florida) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Jfk Medical Center | Atlantis, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Anesthesia Physician Solutions Of South Florida, Llc | 4688805286 | 220 |
News Archive
Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced today that Kaan Medikal will serve as the exclusive distributor of Saladax's My5-FU diagnostic test throughout the Turkish market.
Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the European Commission, acting on the positive recommendation from the European Medicines Agency Committee for Orphan Medicinal Products (COMP), has granted orphan drug designation to synthetic hypericin (the active pharmaceutical ingredient in SGX301) for the treatment of cutaneous T-cell lymphoma (CTCL), a rare disease and a class of non-Hodgkin's lymphoma, a type of cancer of the white blood cells that are an integral part of the immune system.
After a year's oral administration of green tea catechins (GTCs), only one man in a group of 32 at high risk for prostate cancer developed the disease, compared to nine out of 30 in a control, according to a team of Italian researchers from the University of Parma and University of Modena and Reggio Emilia led by Saverio Bettuzzi, Ph.D.
XenoPort, Inc. announced today its financial results for the first quarter ended March 31, 2012. Revenues for the quarter were $10.4 million, compared to $0.4 million for the same period in 2011.
The Ontario Institute for Cancer Research today announced the Cancer Therapeutics Innovation Pipeline initiative and the first 10 projects selected in CTIP's inaugural round of funding.
› Verified 2 days ago
| Entity Name | Sheridan Healthcorp Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629781711 PECOS PAC ID: 3173429693 Enrollment ID: O20031208000355 |
News Archive
Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced today that Kaan Medikal will serve as the exclusive distributor of Saladax's My5-FU diagnostic test throughout the Turkish market.
Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the European Commission, acting on the positive recommendation from the European Medicines Agency Committee for Orphan Medicinal Products (COMP), has granted orphan drug designation to synthetic hypericin (the active pharmaceutical ingredient in SGX301) for the treatment of cutaneous T-cell lymphoma (CTCL), a rare disease and a class of non-Hodgkin's lymphoma, a type of cancer of the white blood cells that are an integral part of the immune system.
After a year's oral administration of green tea catechins (GTCs), only one man in a group of 32 at high risk for prostate cancer developed the disease, compared to nine out of 30 in a control, according to a team of Italian researchers from the University of Parma and University of Modena and Reggio Emilia led by Saverio Bettuzzi, Ph.D.
XenoPort, Inc. announced today its financial results for the first quarter ended March 31, 2012. Revenues for the quarter were $10.4 million, compared to $0.4 million for the same period in 2011.
The Ontario Institute for Cancer Research today announced the Cancer Therapeutics Innovation Pipeline initiative and the first 10 projects selected in CTIP's inaugural round of funding.
› Verified 2 days ago
| Entity Name | Jupiter Anesthesia Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700073848 PECOS PAC ID: 0547348211 Enrollment ID: O20080421000429 |
News Archive
Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced today that Kaan Medikal will serve as the exclusive distributor of Saladax's My5-FU diagnostic test throughout the Turkish market.
Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the European Commission, acting on the positive recommendation from the European Medicines Agency Committee for Orphan Medicinal Products (COMP), has granted orphan drug designation to synthetic hypericin (the active pharmaceutical ingredient in SGX301) for the treatment of cutaneous T-cell lymphoma (CTCL), a rare disease and a class of non-Hodgkin's lymphoma, a type of cancer of the white blood cells that are an integral part of the immune system.
After a year's oral administration of green tea catechins (GTCs), only one man in a group of 32 at high risk for prostate cancer developed the disease, compared to nine out of 30 in a control, according to a team of Italian researchers from the University of Parma and University of Modena and Reggio Emilia led by Saverio Bettuzzi, Ph.D.
XenoPort, Inc. announced today its financial results for the first quarter ended March 31, 2012. Revenues for the quarter were $10.4 million, compared to $0.4 million for the same period in 2011.
The Ontario Institute for Cancer Research today announced the Cancer Therapeutics Innovation Pipeline initiative and the first 10 projects selected in CTIP's inaugural round of funding.
› Verified 2 days ago
| Entity Name | St Lucie Anesthesia Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700044252 PECOS PAC ID: 4284792706 Enrollment ID: O20081027000765 |
News Archive
Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced today that Kaan Medikal will serve as the exclusive distributor of Saladax's My5-FU diagnostic test throughout the Turkish market.
Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the European Commission, acting on the positive recommendation from the European Medicines Agency Committee for Orphan Medicinal Products (COMP), has granted orphan drug designation to synthetic hypericin (the active pharmaceutical ingredient in SGX301) for the treatment of cutaneous T-cell lymphoma (CTCL), a rare disease and a class of non-Hodgkin's lymphoma, a type of cancer of the white blood cells that are an integral part of the immune system.
After a year's oral administration of green tea catechins (GTCs), only one man in a group of 32 at high risk for prostate cancer developed the disease, compared to nine out of 30 in a control, according to a team of Italian researchers from the University of Parma and University of Modena and Reggio Emilia led by Saverio Bettuzzi, Ph.D.
XenoPort, Inc. announced today its financial results for the first quarter ended March 31, 2012. Revenues for the quarter were $10.4 million, compared to $0.4 million for the same period in 2011.
The Ontario Institute for Cancer Research today announced the Cancer Therapeutics Innovation Pipeline initiative and the first 10 projects selected in CTIP's inaugural round of funding.
› Verified 2 days ago
| Entity Name | Anesthesia Physician Solutions Of South Florida, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104248699 PECOS PAC ID: 4688805286 Enrollment ID: O20140325000665 |
News Archive
Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced today that Kaan Medikal will serve as the exclusive distributor of Saladax's My5-FU diagnostic test throughout the Turkish market.
Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the European Commission, acting on the positive recommendation from the European Medicines Agency Committee for Orphan Medicinal Products (COMP), has granted orphan drug designation to synthetic hypericin (the active pharmaceutical ingredient in SGX301) for the treatment of cutaneous T-cell lymphoma (CTCL), a rare disease and a class of non-Hodgkin's lymphoma, a type of cancer of the white blood cells that are an integral part of the immune system.
After a year's oral administration of green tea catechins (GTCs), only one man in a group of 32 at high risk for prostate cancer developed the disease, compared to nine out of 30 in a control, according to a team of Italian researchers from the University of Parma and University of Modena and Reggio Emilia led by Saverio Bettuzzi, Ph.D.
XenoPort, Inc. announced today its financial results for the first quarter ended March 31, 2012. Revenues for the quarter were $10.4 million, compared to $0.4 million for the same period in 2011.
The Ontario Institute for Cancer Research today announced the Cancer Therapeutics Innovation Pipeline initiative and the first 10 projects selected in CTIP's inaugural round of funding.
› Verified 2 days ago
| Entity Name | Fpra Anesthesia Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952756728 PECOS PAC ID: 0547554099 Enrollment ID: O20160808000431 |
News Archive
Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced today that Kaan Medikal will serve as the exclusive distributor of Saladax's My5-FU diagnostic test throughout the Turkish market.
Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the European Commission, acting on the positive recommendation from the European Medicines Agency Committee for Orphan Medicinal Products (COMP), has granted orphan drug designation to synthetic hypericin (the active pharmaceutical ingredient in SGX301) for the treatment of cutaneous T-cell lymphoma (CTCL), a rare disease and a class of non-Hodgkin's lymphoma, a type of cancer of the white blood cells that are an integral part of the immune system.
After a year's oral administration of green tea catechins (GTCs), only one man in a group of 32 at high risk for prostate cancer developed the disease, compared to nine out of 30 in a control, according to a team of Italian researchers from the University of Parma and University of Modena and Reggio Emilia led by Saverio Bettuzzi, Ph.D.
XenoPort, Inc. announced today its financial results for the first quarter ended March 31, 2012. Revenues for the quarter were $10.4 million, compared to $0.4 million for the same period in 2011.
The Ontario Institute for Cancer Research today announced the Cancer Therapeutics Innovation Pipeline initiative and the first 10 projects selected in CTIP's inaugural round of funding.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Richard E Priday, CRNA 1613 N. Harrison Parkway, Suite 200, Mailstop Sh-9a, Sunrise, FL 33323-2896 Ph: (954) 838-2371 | Mr Richard E Priday, CRNA 5301 South Congress Ave, Atlantis, FL 33462 Ph: (561) 965-7300 |
News Archive
Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced today that Kaan Medikal will serve as the exclusive distributor of Saladax's My5-FU diagnostic test throughout the Turkish market.
Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the European Commission, acting on the positive recommendation from the European Medicines Agency Committee for Orphan Medicinal Products (COMP), has granted orphan drug designation to synthetic hypericin (the active pharmaceutical ingredient in SGX301) for the treatment of cutaneous T-cell lymphoma (CTCL), a rare disease and a class of non-Hodgkin's lymphoma, a type of cancer of the white blood cells that are an integral part of the immune system.
After a year's oral administration of green tea catechins (GTCs), only one man in a group of 32 at high risk for prostate cancer developed the disease, compared to nine out of 30 in a control, according to a team of Italian researchers from the University of Parma and University of Modena and Reggio Emilia led by Saverio Bettuzzi, Ph.D.
XenoPort, Inc. announced today its financial results for the first quarter ended March 31, 2012. Revenues for the quarter were $10.4 million, compared to $0.4 million for the same period in 2011.
The Ontario Institute for Cancer Research today announced the Cancer Therapeutics Innovation Pipeline initiative and the first 10 projects selected in CTIP's inaugural round of funding.
› Verified 2 days ago
Joseph J Catalina, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 5301 S Congress Ave, Atlantis, FL 33462 Phone: 561-965-7300 | |
Heather N Stokes, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 5301 S Congress Ave, Atlantis, FL 33462 Phone: 561-965-7300 | |
Danielle Witkowski, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 5301 S Congress Ave, Atlantis, FL 33462 Phone: 561-965-7300 Fax: 954-514-3979 | |
Lidiya Pastukh, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 5301 S Congress Ave, Atlantis, FL 33462 Phone: 561-965-7300 | |
Eileen O'hara, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 5301 S Congress Ave, Atlantis, FL 33462 Phone: 561-965-7300 | |
Jennifer Vanetti Quinn, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 5301 S Congress Ave, Jfk Medical Center, Atlantis, FL 33462 Phone: 561-965-7300 | |
Priscilla Dias, RN Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 5301 S. Congress Ave, Jfk Medical Center,, Atlantis, FL 33462 Phone: 561-548-9275 |